Vela Diagnostics, Singapore, has announced the CE-IVD launch of the Sentosa SA Direct MRSA/SA PCR test, which provides real-time PCR qualitative detection of Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA/SA infections in healthcare settings. Validated for use with the Sentosa SX Lysis Beads and Sentosa SA Reporter, the Sentosa SA Direct allows laboratories to differentiate MRSA from SA. It also identifies a broad range of SCCmec cassette types (Type I to VIII XI), as well as the mecA and novel mecC genes.
S. aureus is a major cause of nosocomial infections, with clinical manifestations ranging from pustules to sepsis and death. It is generally transmitted through contaminated hands. The MRSA bacterium is a strain of S. aureus that has developed resistance to beta-lactam antibiotics and is associated with high morbidity, mortality, and costs. In the United States, there are at least 80,000 severe MRSA infections per year leading to 11,000 deaths.
“With the addition of the newly launched CE-IVD marked Sentosa SA Direct MRSA/SA PCR Test, we offer clinicians an array of molecular tests to aid the overall management of hospital-acquired infection. We are well on track this year to provide clinicians with a complete portfolio of qPCR tests on a single platform,” said Michael Tillmann, CEO of Vela Diagnostics.
For more information, visit Vela Diagnostics.
